Non-HDL cholesterol goal attainment and its relationship with triglyceride concentrations among diabetic subjects with cardiovascular disease: A nationwide survey of 2674 individuals inHungary

Atherosclerosis

Volumn 241, Issue 1, 2015, Pages 62-68

  Mark, Laszlo ^a   Vallejo Vaz, Antonio J ^b   Reiber, Istvan ^c   Paragh, György ^d   Kondapally Seshasai, Sreenivasa Rao ^b   Ray, Kausik K ^e  

^a Pandy Kalman Bekes County Hospital   (Hungary)

^b ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^c 4th Department of Medicine   (Hungary)

^d UNIVERSITY OF DEBRECEN   (Hungary)

^e IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Cardiovascular disease; Diabetes mellitus; LDL cholesterol; Non HDL cholesterol; Remnants; Triglyceride rich lipoproteins; Triglycerides

Indexed keywords

BIOLOGICAL MARKER; CHOLESTEROL ESTER; HEMOGLOBIN A1C; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NON HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; TRIGLYCERIDE RICH LIPOPROTEIN CHOLESTEROL; UNCLASSIFIED DRUG; ANTILIPEMIC AGENT; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONCENTRATION (PARAMETERS); DIABETES MELLITUS; DIABETIC PATIENT; DISEASE ASSOCIATION; FEMALE; GOAL ATTAINMENT; HEALTH SURVEY; HIGH RISK PATIENT; HUMAN; HUNGARY; MAJOR CLINICAL STUDY; MALE; MEDICAL SPECIALIST; MIDDLE AGED; NORMAL VALUE; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL; AGED; BLOOD; CARDIOVASCULAR DISEASES; CHI SQUARE DISTRIBUTION; COMORBIDITY; DYSLIPIDEMIAS; HEALTH CARE SURVEY; METABOLISM; MOTIVATION; MULTIVARIATE ANALYSIS; ODDS RATIO; PRACTICE GUIDELINE; PROTOCOL COMPLIANCE; RISK FACTOR; STATISTICAL MODEL; TREATMENT OUTCOME;

AGED; BIOMARKERS; CARDIOVASCULAR DISEASES; CHI-SQUARE DISTRIBUTION; CHOLESTEROL, HDL; COMORBIDITY; DIABETES MELLITUS; DYSLIPIDEMIAS; FEMALE; GOALS; GUIDELINE ADHERENCE; HEALTH CARE SURVEYS; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HUNGARY; HYPOLIPIDEMIC AGENTS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PRACTICE GUIDELINES AS TOPIC; RISK FACTORS; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 84928884892     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2015.04.810     Document Type: Article

References (27)

1. Emerging Risk Factors Collaboration Diabetes mellitus, fasting glucose, and risk of cause-Specific Death. N.Engl. J. Med. 2011, 364:829-841. 10.1056/NEJMoa1008862.
2. Epidemiology of Cardiovascular Disease Institute of Medicine (US) Committee on Preventing the Global Epidemic of Cardiovascular Disease: Meeting the Challenges in Developing Countries 2010, National Academies Press (US), Washington (DC). V. Fuster, B.B. Kelly (Eds.).
3. Perk J., De Backer G., Gohlke H., Graham I., Reiner Z., Verschuren W.M.M., Albus C., Benlian P., Boysen G., Cifkova R., Deaton C., Ebrahim S., Fisher M., Germano G., Hobbs R., Hoes A., Karadeniz S., Mezzani A., Prescott E., Ryden L., Scherer M., Syvanne M., Scholte Op Reimer W.J.M., Vrints C., Wood D., Zamorano J.L., Zannad F. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). Eur. Heart J. 2012, 33:1635-1701. 10.1093/eurheartj/ehs092.
4. Reiner Z., Catapano A.L., De Backer G., Graham I., Taskinen M.R., Wiklund O., Agewall S., Alegria E., Chapman M.J., Durrington P., Erdine S., Halcox J., Hobbs R., Kjekshus J., Filardi P.P., Riccardi G., Storey R.F., Wood D. ESC/EAS guidelines for the management of dyslipidaemias. Eur. Heart J. 2011, 32:1769-1818. 10.1093/eurheartj/ehr158.
5. Rydén L., Grant P.J., Anker S.D., Berne C., Cosentino F., Danchin N., Deaton C., Escaned J., Hammes H.P., Huikuri H., Marre M., Marx N., Mellbin L., Ostergren J., Patrono C., Seferovic P., Uva M.S., Taskinen M.R., Tendera M., Tuomilehto J., Valensi P., Zamorano J.L. ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur. Heart J. 2013, 34:3035-3087. 10.1093/eurheartj/eht108.
6. Ray K.K., Kastelein J.J.P., Boekholdt S.M., Nicholls S.J., Khaw K.T., Ballantyne C.M., Catapano A.L., Reiner Z., Luscher T.F. The ACC/AHA 2013 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: the good the bad and the uncertain: a comparison with ESC/EAS guidelines for the management of dyslipidaemias 2011. Eur. Heart J. 2014, 35:960-968. 10.1093/eurheartj/ehu107.
7. Grundy S.M., Cleeman J.I., Merz C.N., Brewer H.B., Clark L.T., Hunninghake D.B., Pasternak R.C., Smith S.C., Stone N.J. Implications of recent clinical trials for the national cholesterol education program adult treatment panel III guidelines. Circulation 2004, 110(2):227-239. 10.1161/01.CIR.0000133317.49796.0E.
8. Mark L., Paragh G., Karadi I., Reiber I., Pados G. Changes in attainment of lipid goals by general practitioners and specialists in patients at high cardiovascular risk in Hungary during 2004-2008. Arch. Med. Sci. 2010, 6(5):695-700. 10.5114/aoms.2010.17083.
9. Mark L., Paragh G., Karadi I., Reiber I., Pados G., Kiss Z. An attempt to make lipid-lowering therapy more effective in Hungary. The results of MULTI GAP 2010 and the PLUS. Program. Arch. Med. Sci. 2011, 7(5):760-766. 10.5114/aoms.2011.25549.
10. Mark L., Paragh G., Karadi I., Reiber I., Pados G., Kiss Z. How can we further improve the LDL-cholesterol target level achievement rate based on the Hungarian MULTI GAP 2011 study results and considering the new European dyslipidemia guidelines?. Arch. Med. Sci. 2012, 8(4):608-613. 10.5114/aoms.2012.30283.
11. Varbo A., Benn M., Nordestgaard B.G. Remnant cholesterol as a cause of ischemic heart disease: evidence, definition, measurement, atherogenicity, high risk patients, and present and future treatment. Pharmacol. Ther. 2014, 141(3):358-367. 10.1016/j.pharmthera.2013.11.008.
12. Janosi A., Ostor E., Borbas S., Kazinczy R., Kali A., Vamos I., Bradak A., Podmaniczky M. Data on secondary prevention of coronary artery disease in Hungary and some changes in the last ten years (EUROASPIRE 1995-2005). Orv. Hetil. 2010, 151(43):1776-1782. 10.1556/OH.2010.28961.
13. Kotseva K., Wood D., De Backer G., De Bacquer D., Pyorala K., Keil U. Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II AND III surveys in eight European countries. Lancet 2009, 373:929-940. 10.1016/S0140-6736(09)60330-5.
14. Li M., Ong K.L., Tse H.F., Cheung B.M.Y. Utilization of lipid lowering medications among adults in the United States 1999-2006. Atherosclerosis 2010, 208:456-460. 10.1016/j.atherosclerosis.2009.08.001.
15. Gaede P., Lund-Andersen H., Parving H.H., Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N.Engl. J. Med. 2008, 358(6):580-591. 10.1056/NEJMoa0706245.
16. Anselmino M., Malmberg K., Ohrvik J., Rydén L. Evidence-based medication and revascularization: powerful tools in the management of patients with diabetes and coronary artery disease: a report from the Euro Heart Survey on diabetes and the heart. Eur. J. Cardiovasc Prev. Rehabil. 2008, 15(2):216-223. 10.1097/HJR.0b013e3282f335d0.
17. Baigent C., Keech A., Kearney P.M., Blackwell L., Buck G., Pollicino C., Kirby A., Sourjina T., Peto R., Collins R., Simes R. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005, 366(9493):1267-1278. 10.1016/S0140-6736(05)67394-1.
18. Gould A.L., Davies G.M., Alemao E., Yin D.D., Cook J.R. Cholesterol reduction yields clinical benefits: meta-analysis including recent trials. Clin. Ther. 2007, 29(5):778-794. 10.1016/j.clinthera.2007.05.012.
19. Emerging Risk Factors Collaboration Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009, 302(18):1993-2000. 10.1001/jama.2009.1619.
20. Robinson J.G., Wang S., Smith B.J., Jacobson T.A. Meta-analysis of the relationship between non-high-density lipoprotein cholesterol reduction and coronary heart disease risk. J.Am. Coll. Cardiol. 2009, 53(4):316-322. 10.1016/j.jacc.2008.10.024.
21. Boekholdt S.M., Arsenault B.J., Mora S., Pedersen T.R., LaRosa J.C., Nestel P.J., Simes R.J., Durrington P., Hitman G.A., Welch K.M., DeMicco D.A., Zwinderman A.H., Clearfield M.B., Downs J.R., Tonkin A.M., Colhoun H.M., Gotto A.M., Ridker P.M., Kastelein J.J. Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins. JAMA 2012, 307(12):1302-1309. 10.1001/jama.2012.366.
22. Chapman M.J., Ginsberg H.N., Amarenco P., Andreotti F., Borén J.C., Catapano A.L., Descamps O.S., Fisher E., Kovanen P.T., Kuivenhoven J.A., Lesnik P., Masana L., Nordestgaard B.G., Ray K.K., Reiner Z., Taskinen M.R., Tokgozoglu L., Tybjærg-Hansen A., Watts G.F. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur. Heart J. 2011, 32:1345-1361. 10.1093/eurheartj/ehr112.
23. Varbo A., Benn M., Tybjaerg-Hansen A., Jorgensen A.B., Frikke-Schmidt R., Nordestgaard B.G. Remnant cholesterol as a causal risk factor for ischemic heart disease. J.Am. Coll. Cardiol. 2013, 61:427-436. 10.1016/j.jacc.2012.08.1026.
24. Davis C.E., Williams D.H., Oganov R.G., Tao S.C., Rywik S.L., Stein Y., Little J.A. Sex difference in high density lipoprotein cholesterol in six countries. Am. J. Epidemiol. 1996, 143(11):1100-1106.
25. Norata G.D., Tibolla G., Catapano A.L. PCSK9 inhibition for the treatment of hypercholesterolemia: promises and emerging challenges. Vasc. Pharmacol. 2014, 62(2):103-111. pii:S1537-1891(14)00107-4. 10.1016/j.vph.2014.05.011.
26. Jun K.R., Park H.I., Chun S., Park H., Min W.K. Effects of total cholesterol and triglyceride on the percentage difference between the low-density lipoprotein cholesterol concentration measured directly and calculated using the Friedewald formula. Clin. Chem. Lab. Med. 2008, 46(3):371-375. 10.1515/CCLM.2008.064.
27. Scharnagl H., Nauck M., Wieland H., März W. The Friedewald formula underestimates LDL cholesterol at low concentrations. Clin. Chem. Lab. Med. 2001, 39(5):426-431. 10.1515/CCLM.2001.068.